|
목적 : To investigate the intraocular pressure (IOP)–lowering efficacy of brinzolamide 1% and brimonidine 0.2% fixed combination (BBFC)(Simbrinza®) in patients with normal tension glaucoma
방법 : The medical records of patients with normal tension glaucoma who underwent BBFC monotherapy as a first drug of choice for more than three months were reviewed retrospectively. All patients were followed up after 1 and 3 months of treatment. The good response to BBFC was defined as more than 20% reduction of IOP from baseline.
결과 : 21 eyes of 21 patients with normal tension glaucoma were enrolled. Overall follow-up period, 15 eyes (71.4%) were observed as responders to BBFC. The mean IOP at the baseline visit was 14.0 mmHg. After treatment with BBFC, the mean IOP decreased to 11.0 mmHg (3.0 mmHg [21.2%] reduction from baseline) at 1 month and to 12.0 mmHg (2.9 mmHg [19.4%] reduction from baseline) at 3 months after treatment, respectively. No significant difference was found in IOP between 1 and 3 months of treatment (P > 0.05). Itching was the most common ocular adverse effect, which was reported in 3 eyes (14.3%).
결론 : BBFC effectively reduced IOP without serious adverse effects in treatment – naïve patients with normal tension glaucoma.
|